Stockscreener 앱 받기
8.50
2.53%
0.21
시간 외 거래:
8.51
0.010
+0.12%
Imunon Inc 주식(IMNN)의 최신 뉴스
Is Imunon Inc. stock overvalued or undervaluedUnlock daily market insights for better decisions - jammulinksnews.com
Is Imunon Inc. a growth stock or a value stockTurn volatility into profit opportunities - jammulinksnews.com
Is Imunon Inc. a good long term investmentPhenomenal returns - jammulinksnews.com
How does Imunon Inc. compare to its industry peersOutstanding yields - jammulinksnews.com
What analysts say about Imunon Inc. stockInvest smarter with data-backed trading alerts - jammulinksnews.com
What catalysts could drive Imunon Inc. stock higher in 2025High-octane investment gains - jammulinksnews.com
How strong is Imunon Inc. company’s balance sheetDiscover hidden gems in the stock market - jammulinksnews.com
How does Imunon Inc. generate profit in a changing economyAccelerate your capital gains today - jammulinksnews.com
Should I hold or sell Imunon Inc. stock in 2025Invest confidently with real-time data - jammulinksnews.com
Published on: 2025-08-03 14:28:27 - jammulinksnews.com
What is the dividend policy of Imunon Inc. stockBuild a diversified portfolio for stability - jammulinksnews.com
When is Imunon Inc. stock expected to show significant growthAchieve rapid portfolio growth with smart picks - jammulinksnews.com
What are the latest earnings results for Imunon Inc.Exceptional return forecasts - jammulinksnews.com
How volatile is Imunon Inc. stock compared to the marketFinancial News Data Feed With High Returns - jammulinksnews.com
Imunon Inc. stock prediction for this weekTrend Analysis for Safer Trades Gains Popularity - metal.it
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 - GlobeNewswire
IMUNON Inc. Stock Rises on Clinical Milestone for Lead Drug Candidate IMNN-001 - AInvest
Imunon stock surges after first patient dosed in Phase 3 ovarian cancer trial - Investing.com Nigeria
Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued - Stocktwits
Imunon announces first patient dosed in Phase 3 OVATION 3 study of IMNN-001 - TipRanks
First patient dosed in IMUNON’s phase 3 ovarian cancer trial By Investing.com - Investing.com India
First patient dosed in IMUNON’s phase 3 ovarian cancer trial - Investing.com
IMUNON Advances Revolutionary Ovarian Cancer Treatment to Phase 3 After Strong Survival Data - Stock Titan
IMUNON to Hold Second Quarter 2025 Financial Results and - GlobeNewswire
IMUNON Earnings Call: Latest Phase 3 Data Coming for DNA-Based Ovarian Cancer Immunotherapy - Stock Titan
Order Book Volume Tilts Bullish on Imunon Inc.Reliable Investment Entry Signals Confirmed by Charts - metal.it
Why Imunon Inc. stock attracts strong analyst attentionEntry Alert With Low Drawdown Strategy Noted - beatles.ru
Imunon Announces 15% Stock Dividend Approval - TipRanks
IMUNON's Strategic Repositioning: Reverse Split and Stock Dividend as Catalysts for Shareholder Value and Nasdaq Compliance - AInvest
IMUNON Announces Stock Dividend Boosting Shareholder Value - The Manila Times
IMUNON Rewards Shareholders with 15% Stock Dividend After Breakthrough Ovarian Cancer Trial Results - Stock Titan
0.93%
0.15%
자본화:
|
볼륨(24시간):